“We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease’s progression,” said Dr. Alexandre Prat, a professor in the Department of Neurosciences at the University of Montreal.
By Stephen Feller | May 20, 2015
Multiple sclerosis is the result of lymphocytes penetrating the brain-blood barrier and disrupting the transmission of nerve impulses. Researchers believe they have identified a primary molecule that helps this to happen. Image by Ralwel/Shutterstock
MONTREAL, May 20 (UPI) — Researchers at the University of Montreal have discovered a treatment that can potentially stop the progression of multiple sclerosis.
The melanoma cell adhesion molecule, or MCAM, was found to be a crucial element in the attacks on the nervous system which slowly incapacitate people with multiple sclerosis. In vitro tests in humans, as well as tests in mice, showed that MCAM can be blocked, delaying onset of the disease and potentially slowing its progress.
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
